Not Approved (US) Longevity & Mitochondrial

Endoluten

also known as: Pineal peptide bioregulator, A-8 (pineal peptide preparation)

The Khavinson pineal bioregulator preparation, positioned as a "precursor/complementary" product to epithalon (the synthetic AEDG tetrapeptide). Marketed in Russia for neuroendocrine and circadian support in aging. Evidence base is Russian-language Khavinson-group studies with minimal independent replication.

A pineal-gland-derived short peptide preparation in the Khavinson cytomedine series, marketed as Endoluten in Russia and CIS markets. Positioned as the natural-extract counterpart to the synthetic tetrapeptide epithalon (Ala-Glu-Asp-Gly / AEDG), which was itself isolated from pineal bioregulator preparations in the 1980s. The regulatory and evidentiary profile is identical to other Khavinson natural-extract cytomedines: Russian nutraceutical status, no FDA/EMA approval, and limited Western peer-reviewed validation.

Mechanism of action

Proposed to support pineal-axis function and melatonin-related signaling by providing pineal-tissue-specific short peptides. The active tetrapeptide characterized from pineal extracts is epithalon (AEDG), which has been reported in Khavinson-group studies to induce telomerase activity, extend replicative lifespan in cell culture, and modestly extend lifespan in rodent models. As with other Khavinson claims, extensions to humans rest on small, methodologically limited Russian clinical studies and require independent replication.

Primary uses

Neuroendocrine aging support (Russian nutraceutical positioning)
Circadian rhythm / sleep-quality support (anecdotal)
Immune-senescence support (Russian clinical positioning)

Typical dosing

1–2 capsules 1–2 times daily in 20–30 day courses (oral)

Russian nutraceutical dosing. Courses typically repeated 2–4 times per year. No controlled clinical evidence supports specific dosing as efficacious in humans.

Regulatory status

Not FDA- or EMA-approved. Sold in Russia and CIS markets as a nutraceutical supplement, not a registered medicine. The synthetic tetrapeptide epithalon, derived from characterization of pineal bioregulator preparations, is itself a research-only compound and is covered in its own encyclopedia entry.

References

[pubmed] Khavinson VK, et al. "Peptide extension of lifespan and normalization of physiological functions in aged mice." Bull Exp Biol Med, 2011;151:480-483.
[review] Anisimov VN, Khavinson VK. "Peptide bioregulation of aging: results and prospects." Biogerontology, 2010;11:139-149.

Related peptides

Epithalon

A synthetic pineal tetrapeptide from the Khavinson group (St. Petersburg) — the only peptide with published data claiming telomerase activation and telomere elongation in human cell models.

Pinealon

A Khavinson tripeptide proposed to cross the blood–brain barrier and support neuronal gene expression in aging brain tissue — animal data in hypoxia and oxidative stress models; no Western clinical trials.

Cerluten

A Khavinson lung-derived short peptide bioregulator sold in Russia as a cytomedine supplement for respiratory aging. Like the rest of the Khavinson short-peptide family, supporting evidence is almost exclusively Russian-language and of low methodological rigor by Western standards; no independent replication, no FDA or EMA status, and no controlled clinical data.

Disclaimer

This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.